Advances in Gastrointestinal Cancers
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Immunotherapy in Gastrointestinal Malignancies
dMMR and PD-1 Blockade
dMMR and PD-1 Blockade (cont)
dMMR and PD-1 Blockade (cont)
Immunotherapy in Hepatocellular Carcinoma
Nivolumab Monotherapy in HCC CheckMate-040
CheckMate-040 Subset Analysis
Pembrolizumab Monotherapy in HCC KEYNOTE-224
Durvalumab Monotherapy in HCC
Dual Checkpoint Inhibitor Therapy in HCC
Combined VEGF Inhibition and PD-1 Inhibition in HCC
Ongoing Trials and Future Directions
Immunotherapy in Gastroesophageal Cancer
Pembrolizumab Monotherapy in Gastric/Gastroesophageal Cancer
Nivolumab Monotherapy in Gastric and GE Junction Cancer
Avelumab Monotherapy in Advanced Gastric or GE Junction Cancer
Pembrolizumab Monotherapy in Gastric and GE Junction Cancer
Dual Checkpoint Inhibitors in Gastric and GE Junction Cancers: Nivolumab + Ipilimumab
Dual Checkpoint Inhibitors in Gastric and GE Junction Cancers: Durvalumab + Tremelimumab
Combination VEGFR-2 and PD-1 Inhibition in the Second Line Management of Gastric or GE Junction Adenocarcinoma
Ongoing Trials and Future Directions
Immunotherapy in Pancreatic Adenocarcinoma
Immunotherapy in Pancreatic Cancer
Dual Checkpoint Inhibitors in Pancreatic Cancer
Chemotherapy in Combination With Checkpoint Inhibitors
Other Immunomodulating Agents IDO-1 Inhibitors
Other Immunomodulating Agents: CSF1R Blockade
Pancreatic Immunotherapy Ongoing trials
Concluding Remarks
Abbreviations
Abbreviations (cont)
Abbreviations (cont)